Malaquias AC, et al. - In patients with Noonan syndrome (NS), researchers assessed the response to recombinant human growth hormone (rhGH) treatment. For this investigation, 42 patients (35 PTPN11+) were treated with rhGH; 17 were followed-up until adult height. Data reported that patients with PTPN11+ had a better response than patients with PTPN11–. According to findings, the advantage of rhGH therapy on adult height in PTPN11+ patients was supported in this analysis. In comparison, patients with PTPN11– had a poor response to rhGH. This PTPN11-group, however, was small, preventing an adequate comparison between different genotypes and no therapy response guarantee in genes other than PTPN11.